NCT00044382View on ClinicalTrials.gov

Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 1, 2002

Primary Completion Date

January 1, 2007

Study Completion Date

January 30, 2007

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

CC-5013

Trial Locations (1)

85724

Arizona Cancer Center, Tucson

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY